News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NeurogesX, Inc. (NGSX) to Cut Jobs


12/3/2012 9:19:51 AM

NeurogesX Inc. will cut nine jobs by the end of the year as it focuses clinical development on its main pain drug. The San Mateo pain treatment developer (OTC BB: NGSX) told employees about the move Thursday. Those workers will receive an undisclosed cash severance, contingent on them signing a general release with the company. NeurogesX said the move will result in a fourth-quarter charge of about $280,000. NeurogesX's main experimental drug, NGX-1998, is a topical liquid formulation to treat postherpetic neuralgia, or pain along a nerve that is associated with shingles.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES